Molecular Biology Reports

, Volume 46, Issue 6, pp 5685–5693 | Cite as

Effect of single nucleotide polymorphisms in SEPS1 and SEPP1 on expression in the protein level in metabolic syndrome in subjects with cardiovascular disease

  • Mojgan Gharipour
  • Khadija OuguerramEmail author
  • El-Hassane Nazih
  • Mansoor Salehi
  • Mehrdad Behmanesh
  • Rouzbeh Razavi
  • Amin Gharipour
  • Minoo Diantkhah
  • Masoumeh Sadeghi
Original Article


Metabolic syndrome (MetS) results from the interaction between environmental and genetic factors. Several previous studies considered the role of selenium in developing MetS. Two selenoproteins, selenoprotein S (SelS), and the Selenoprotein P (SePP) play an important role in antioxidative defense and therefore susceptibility to MetS. The involvement of SNPs in SEPP1 and SEPS1 have not been studied in MetS subjects. This study aims to investigate the association between the risk of MetS and four polymorphisms SEPS1 (rs28665122, rs4965373), SEPP1 (rs7579, rs3877899) in an Iranian population. The sample of this case–control study consisted of 132 Iranian patients with cardiovascular disease (71 MetS and 65 non-MetS subjects) from December 2015 to March 2016. Demographic data, medical history, and para-clinical were measured, and Taqman probes were used for allelic discrimination. The level of the SelS and the SePP were measured by the ELIZA method. No significant differences were found in the genotype frequencies of SEPS1 (rs4965373, rs28665122), SEPP1 (rs7579, rs3877899) in patients with MetS and the non-MetS group. The mean of SelS in MetS subjects with SEPS1 (rs4965373) GG genotype is significantly lower than the non-MetS group (4496.99 ± 3688.5 vs. 6148.6 ± 1127.0, P = 0.009). The mean of SePP in MetS subjects with SEPP1 (rs3877899) GG genotype is significantly lower than the non-MetS group (40.73 ± 8.44 vs.83.91 ± 21.33, P = 0.002). The mean of SePP in MetS subjects with SEPP1 (rs7579) GG genotype is lower than the non-MetS group (55.52 ± 16.7 vs. 109.48 ± 29.78, P = 0.01). In summary, the results of this study does not indicate significant differences in the SEPP1 (rs7579, rs3877899) and SEPS1 (rs4965373, rs28665122) genotypes between MetS and non-MetS subjects. However, the results show that the mean of expression of SelS and SePP decreased in the subjects with SEPP1 (rs7579) GG and SEPP1 (rs3877899) GG.


Polymorphisms SEPS1 SEPP1 SelS SePP Gene Metabolic syndrome Cardiovascular disease 



This study was a part of a PhD thesis. The authors are grateful to the Nantes University, France, for its contribution to the study. We thank the Genetic Laboratory staff of Nantes University for running Taqman analysis and the Staff of the Biochemistry Laboratory of Cardiovascular Research Institute, Isfahan University of Medical Sciences, Mrs. Elham Khosravi and Mrs. Zahra Jabar are thanked for their skillful contribution in the ELIZA and biochemistry analysis. The authors also acknowledge volunteers who took part in the study and appreciate their time and involvement in the study.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest.


  1. 1.
    Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356–359CrossRefGoogle Scholar
  2. 2.
    Gharipour M et al (2015) Effect of age on the phenotype of metabolic syndrome in developing country. Adv Biomed Res 4:103PubMedPubMedCentralGoogle Scholar
  3. 3.
    Gharipour M et al (2017) Selenium homeostasis and clustering of cardiovascular risk factors: a systematic review. Acta Bio Med Atenei Parmensis 88(3):263–270Google Scholar
  4. 4.
    Tinggi U (2008) Selenium: its role as antioxidant in human health. Environ Health Prev Med 13(2):102CrossRefGoogle Scholar
  5. 5.
    Hayden MR, Tyagi SC (2004) Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J 3(1):4CrossRefGoogle Scholar
  6. 6.
    Méplan C (2015) Selenium and chronic diseases: a nutritional genomics perspective. Nutrients 7(5):3621–3651CrossRefGoogle Scholar
  7. 7.
    Hart K et al (2011) A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer 71(2):123–129CrossRefGoogle Scholar
  8. 8.
    Curran JE et al (2005) Genetic variation in selenoprotein S influences inflammatory response. Nat Genet 37(11):1234CrossRefGoogle Scholar
  9. 9.
    Méplan C, Hesketh J (2014) Selenium and cancer: a story that should not be forgotten-insights from genomics. Adv Nutr Cancer. Springer, Berlin, p 145–166Google Scholar
  10. 10.
    Pellatt AJ et al (2013) SEPP1 influences breast cancer risk among women with greater native american ancestry: the breast cancer health disparities study. PLoS ONE 8(11):e80554CrossRefGoogle Scholar
  11. 11.
    Moses EK et al (2008) Genetic association of preeclampsia to the inflammatory response gene SEPS1. Am J Obstet Gynecol 198(3):336CrossRefGoogle Scholar
  12. 12.
    Altinova AE et al (2015) Selenoprotein P is not elevated in gestational diabetes mellitus. Gynecol Endocrinol 31(11):874–876CrossRefGoogle Scholar
  13. 13.
    Burk RF, Hill KE (1994) Selenoprotein P. A selenium-rich extracellular glycoprotein. J Nutr 124(10):1891–1897PubMedGoogle Scholar
  14. 14.
    Mao J et al (2015) Genetic polymorphisms that affect selenium status and response to selenium supplementation in United Kingdom pregnant women. Am J Clin Nutr 103(1):100–106CrossRefGoogle Scholar
  15. 15.
    Méplan C et al (2009) Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal 11(11):2631–2640CrossRefGoogle Scholar
  16. 16.
    Gharipour M et al (2017) Association of expression of selenoprotein P in mRNA and protein levels with metabolic syndrome in subjects with cardiovascular disease: results of the Selenegene study. J Gene Med 19(3):e2945CrossRefGoogle Scholar
  17. 17.
    Martínez A et al (2008) Polymorphisms in the selenoprotein S gene: lack of association with autoimmune inflammatory diseases. BMC Genomics 9(1):329CrossRefGoogle Scholar
  18. 18.
    Miller S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefGoogle Scholar
  19. 19.
    Kannan S et al (2014) LDL-cholesterol: friedewald calculated versus direct measurement-study from a large Indian laboratory database. Indian J Endocrinol Metab 18(4):502CrossRefGoogle Scholar
  20. 20.
    Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27(10):2444–2449CrossRefGoogle Scholar
  21. 21.
    Vunta H et al (2008) Selenium attenuates pro-inflammatory gene expression in macrophages. Mol Nutr Food Res 52(11):1316–1323CrossRefGoogle Scholar
  22. 22.
    Martínez A, Santiago JL, Varadé J, Márquez A, Lamas JR, Mendoza JL, de la Calle H, Díaz-Rubio M, de la Concha EG, Fernández-Gutiérrez B, Urcelay E (2008) Polymorphisms in the selenoprotein S gene: lack of association with autoimmune inflammatory diseases. BMC Genomics 14(9):329CrossRefGoogle Scholar
  23. 23.
    Karunasinghe N, Han DY, Zhu S et al (2012) Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland. New Zealand. Genes Nutr 7(2):179–190. CrossRefPubMedGoogle Scholar
  24. 24.
    Hyrenbach S et al (2007) No association of the-105 promoter polymorphism of the selenoprotein S encoding gene SEPS1 with cerebrovascular disease. Eur J Neurol 14(10):1173–1175CrossRefGoogle Scholar
  25. 25.
    Rueli RH, Torres DJ, Dewing AS et al (2017) Selenoprotein S reduces endoplasmic reticulum stress-induced phosphorylation of tau: potential role in selenate mitigation of tau pathology. J Alzheimers Dis 55(2):749–762. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Schmidt FM et al (2015) Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS ONE 10(3):e0121971CrossRefGoogle Scholar
  27. 27.
    de Oliveira Silva A et al (2013) Inflammatory status in older women with and without metabolic syndrome: is there a correlation with risk factors? Clin Interv Aging 8:361CrossRefGoogle Scholar
  28. 28.
    Pickup J, Crook M (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41(10):1241–1248CrossRefGoogle Scholar
  29. 29.
    Engström G et al (2003) Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 52(8):2097–2101CrossRefGoogle Scholar
  30. 30.
    Newson R et al (2014) The association of asthma, nasal allergies, and positive skin prick tests with obesity, leptin, and adiponectin. Clin Exp Allergy 44(2):250–260CrossRefGoogle Scholar
  31. 31.
    Ogbera AO et al (2013) Cytokines, Type 2 DM and the Metabolic Syndrome. Niger Q J Hosp Med 23(4):318–322Google Scholar
  32. 32.
    Sun H-Y et al (2016) Single nucleotide polymorphism in the SEPS1 gene may contribute to the risk of various human diseases: a meta-analysis. Ann Hum Biol 43(5):469–479CrossRefGoogle Scholar
  33. 33.
    Cox AJ et al (2013) Polymorphisms in the Selenoprotein S gene and subclinical cardiovascular disease in the Diabetes Heart Study. Acta Diabetol 50(3):391–399CrossRefGoogle Scholar
  34. 34.
    Park K et al (2012) Toenail selenium and incidence of type 2 diabetes mellitus in US men and women. Diabetes Care 35(7):1544–1551CrossRefGoogle Scholar
  35. 35.
    Czernichow S et al (2006) Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU. VI. MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr 84(2):395–399PubMedGoogle Scholar
  36. 36.
    Akbaraly TN et al (2010) Plasma selenium and risk of dysglycemia in an elderly French population: results from the prospective epidemiology of vascular ageing Study. Nutr Metab 7(1):21CrossRefGoogle Scholar
  37. 37.
    Rayman MP et al (2012) A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS ONE 7(9):e45269CrossRefGoogle Scholar
  38. 38.
    Méplan C et al (2007) Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J 21(12):3063–3074CrossRefGoogle Scholar
  39. 39.
    Ishikura K et al (2014) Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells. Diabetologia 57(9):1968–1976CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Mojgan Gharipour
    • 1
  • Khadija Ouguerram
    • 2
    Email author
  • El-Hassane Nazih
    • 3
  • Mansoor Salehi
    • 4
  • Mehrdad Behmanesh
    • 5
  • Rouzbeh Razavi
    • 6
  • Amin Gharipour
    • 7
  • Minoo Diantkhah
    • 1
  • Masoumeh Sadeghi
    • 8
  1. 1.Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical SciencesIsfahanIran
  2. 2.UMR PHAN, INRA & Université de Nantes, IMAD, CRNH-OuestNantesFrance
  3. 3.IUML—Institut Universitaire Mer et Littoral—FR3473 CNRSNantesFrance
  4. 4.Department of Genetics and Molecular Biology Medical SchoolIsfahan University of Medical SciencesIsfahanIran
  5. 5.Department of Genetics, Faculty of Biological SciencesTarbiat Modares UniversityTehranIran
  6. 6.Department of Management and Information SystemsKent State UniversityKentUSA
  7. 7.Department of Accounting, Finance and EconomicsGriffith UniversityGold Coast CampusAustralia
  8. 8.Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical SciencesIsfahanIran

Personalised recommendations